{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Haleos Labs Limited
Haleos Labs Limited is Rated Hold by MarketsMOJO
Haleos Labs Limited is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure
Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 26 Dec 2025, hitting the lower circuit limit and registering one of the steepest single-day declines in recent times. The stock’s performance contrasted sharply with broader market indices and its sector peers, reflecting a wave of panic selling and unfilled supply on the trading floor.
Haleos Labs Limi Sees Revision in Market Evaluation Amid Mixed Financial Signals
Haleos Labs Limi has undergone a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial developments and valuation considerations. The pharmaceutical and biotechnology company’s assessment now indicates a more balanced outlook, influenced by changes across quality, valuation, financial trends, and technical factors.
Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure
Shares of Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, faced intense selling pressure on 18 Dec 2025, hitting the lower circuit limit and registering a maximum daily loss of 5.0%. The stock closed at ₹1,232.4, marking a significant decline amid subdued investor participation and unfilled supply on the order books.
Haleos Labs Limited Hits Lower Circuit Amid Heavy Selling Pressure
Haleos Labs Limited, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 17 Dec 2025 as the stock hit its lower circuit limit, reflecting intense selling pressure and a maximum daily loss of 5.0%. The stock’s performance notably lagged behind its sector and broader market indices, signalling a day marked by panic selling and unfilled supply.
Haleos Labs Limited Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals
Haleos Labs Limited, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation following a combination of recent financial results and technical market indicators. The company’s performance over various timeframes, alongside its valuation and technical trends, has prompted a nuanced reassessment of its investment profile.
How has been the historical performance of Haleos Labs Limi?
Haleos Labs Limi showed improved financial performance in Mar'25, with net sales rising to 344.72 Cr and profit after tax increasing to 18.73 Cr, up from 6.33 Cr in the previous year. The company also reported enhanced operational efficiency, reflected in a significant rise in operating profit to 49.90 Cr.
Haleos Labs Limited Forms Golden Cross, Signalling Potential Bullish Breakout
Haleos Labs Limited has recently experienced a significant technical event known as the Golden Cross, where its 50-day moving average has crossed above the 200-day moving average. This development is widely regarded as a bullish signal, indicating a possible shift in long-term momentum and a potential trend reversal for the pharmaceutical and biotechnology company.
SMS Lifesciences India: Analytical Review Highlights Shift in Market Assessment
SMS Lifesciences India has experienced a notable revision in its market evaluation, reflecting changes across multiple analytical parameters including quality, valuation, financial trends, and technical indicators. This comprehensive review examines the factors influencing the current market perspective on the pharmaceutical and biotechnology company.
Why is SMS Lifesciences falling/rising?
On 21-Nov, SMS Lifesciences India Ltd witnessed a significant rise in its share price, closing at ₹1,418.20 with a gain of ₹92.5 or 6.98%. This upward momentum reflects a combination of robust financial results, favourable valuation metrics, and heightened investor participation, positioning the stock well above key moving averages and outperforming broader market benchmarks.
SMS Lifesciences India Reports Strong Growth Amid Mixed Long-Term Performance Indicators
SMS Lifesciences India has recently experienced an evaluation adjustment reflecting significant changes in its financial metrics. For the quarter ending September 2025, the company reported strong growth in key indicators, including Profit Before Tax and a favorable Debt-Equity Ratio, while also achieving notable earnings per share.
How has been the historical performance of SMS Lifesciences?
SMS Lifesciences showed improved financial performance in Mar'25, with net sales rising to 344.72 Cr and profit before tax increasing to 26.19 Cr, despite a decline from Mar'22 levels. The company also reported a significant rise in operating profit margin and earnings per share, indicating a recovery in profitability and operational efficiency.
Why is SMS Lifesciences falling/rising?
As of 14-Nov, SMS Lifesciences India Ltd is currently priced at 1,311.00, reflecting a 4.29% increase and strong performance over the past week. Despite impressive returns and outperformance against the Sensex, a significant drop in delivery volume raises concerns about the sustainability of this price increase.
How has been the historical performance of SMS Lifesciences?
SMS Lifesciences has shown fluctuating historical performance, with net sales increasing to 344.72 Cr in March 2025, alongside significant growth in profits, including a profit before tax rise to 26.19 Cr. The company has demonstrated improved operational efficiency and positive cash flow trends in recent years.
Are SMS Lifesciences latest results good or bad?
SMS Lifesciences' latest results show a 30.62% year-on-year profit growth to ₹6.10 crores and improved operating margins, but revenue declined slightly, indicating challenges in sales growth and below-average return on equity. Overall, the performance is mixed, suggesting a complex financial environment for the company.
SMS Lifesciences Q2 FY26: Margin Revival Masks Deeper Quality Concerns
SMS Lifesciences India Ltd., a Hyderabad-based pharmaceutical company with a market capitalisation of ₹361.89 crores, reported a consolidated net profit of ₹6.10 crores in Q2 FY26, marking a significant sequential recovery of 46.63% from ₹4.16 crores in Q1 FY26. Year-on-year, the company posted growth of 30.62% from ₹4.67 crores in Q2 FY25. Despite this encouraging quarterly performance, the stock has struggled over the past year, declining 6.67% whilst the broader market gained 4.60%, reflecting persistent investor concerns about the company's long-term quality metrics and profitability consistency.
Why is SMS Lifesciences falling/rising?
As of 03-Nov, SMS Lifesciences India Ltd is priced at Rs 1,212.00, showing a recent upward trend with a 5.94% return over the last three days. Despite short-term gains, the stock has underperformed the Sensex year-to-date and over the past year.
Why is SMS Lifesciences falling/rising?
As of 26-Sep, SMS Lifesciences India Ltd's stock price has declined to 1,145.00, down 4.15%, and is significantly underperforming its sector and the overall market. The stock shows weak fundamentals, with a low ROCE of 9.00% and a year-over-year return of -22.74%, contributing to declining investor confidence.
Why is SMS Lifesciences falling/rising?
As of 22-Sep, SMS Lifesciences India Ltd is seeing a price increase to Rs 1,227.00, with a 1-week return of 1.91% and a 1-month return of 5.78%. Despite recent gains, the stock has weak long-term fundamentals and declining profit trends, indicating mixed market conditions.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
